Outcomes of MF Patients Exposure to Ruxolitinib During Transplantation
Not Applicable
- Conditions
- Time of Hematopoietic Reconstruction
- Interventions
- Other: comprehensive treatment regimen
- Registration Number
- NCT04526223
- Lead Sponsor
- xuna
- Brief Summary
Increasing experience of Ruxolitinib pre-allo SCT and data concerning Ruxolitinib during transplantation
1. Diagnosis MF(includ Post-ET,Post-PV,PMF,MDS/MPN with MF)
2. With at least two month Ruxolitinib treatment prior to transplantation
3. DAC+BF as myeloablative conditioning regimen
4. CSA from day -3 and MMF from day +1 until day 28 ATG Neovii® at dose of 7.5mg/KG for mismatch donor
5. received Rux at +6d in ASCT and continued to +60d
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
- Age 18-60 years old, gender is not limited;
- Diagnosis MF(includ Post-ET,Post-PV,PMF) according to 2016 WHO
- With at least two month Ruxolitinib treatment before transplantation
- Informed consent of the patient or his legal representative
Exclusion Criteria
- HCT-CI score≥2
- Woman who is pregnant or nursing
- MPN Patients who have received allogeneic hematopoietic stem cell transplantation
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description treatment group comprehensive treatment regimen MF patients exposure to ruxolitinib during transplantation
- Primary Outcome Measures
Name Time Method Time of neutrophils reconstruction 1 year Neutrophils count≧0.5G/L without G-CSF
- Secondary Outcome Measures
Name Time Method The incidence rate of GVHD 1 year The incidence rate of aGVHD and cGVHD
Trial Locations
- Locations (1)
NanfangH
🇨🇳Guangzhou, Guangdong, China